Abstracts tagged "adalimumab and rheumatoid arthritis (RA)"

Abstract Number: 1448 • 2017 ACR/ARHP Annual Meeting
Prospective, Intervention, Multicenter, Non-Inferiority Study of Utility of Therapeutic Drug Monitoring with Respect to the Efficacy and Cost of Adalimumab Tapering in Patients with Rheumatic Diseases
Catalina Gómez Arango¹, Maria Luz Garcia Vivar², Eduardo Úcar Angulo¹, Iñigo Gorostiza³, Clara Eugenia Perez², Juan Ramon De Dios⁴, Belen Alvarez⁵, Ana Ruibal Escribano⁶, Claudia Stoye⁵, Margarida Vasques⁵, Joaquin Belzunegui Otano⁷, Antonio Escobar³, Ziortza Trancho⁸, Ainhoa Ruiz del Agua⁹, Lorena Del Rio⁹, Cristina Jorquera¹⁰, Antonio Martínez⁹ and Daniel Nagore⁹, ¹Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²RHEUMATOLOGY, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Research Unit, Basurto Univeristy Hospital, Bilbao, Spain, ⁴Rheumatology Department. Hospital Universitario de Araba, Vitoria, Spain, ⁵Rheumatology, Hospital Universitario de Araba, Vitoria, Spain, ⁶Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ⁷Donostia University Hospital, San Sebastian, Spain, ⁸Unidad de Investigación, Hospital Universitario de Basurto, Bilbao, Spain, ⁹R&D, Progenika-Grifols, Derio, Spain, ¹⁰Hospital Universitario de Basurto, Bilbao, Spain
Background/Purpose: Adalimumab (ADL) tapering based on clinical assessment is an usual practice, especially in patients in remission. The objective of INGEBIO was to analyze how…
Abstract Number: 1268 • 2016 ACR/ARHP Annual Meeting
Hand Bone Loss in Early Rheumatoid Arthritis Is Independent of Adalimumab Treatment – Results from a Randomized Controlled Clinical Trial.
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard², Trine David Jensen³, Kim Hørslev-Petersen⁴, Kristian Stengaard-Pedersen⁵, Peter Junker⁶, Torkell Ellingsen⁷, Palle Ahlquist⁸, Hanne Lindegaard⁹, Asta Linauskas¹⁰, Annette Schlemmer¹¹, Mette Yde Dam⁷, Ib Hansen¹², Tine Lottenburger⁸, Christian G. Ammitzbøll⁵, Anette Jørgensen⁵, Sophine B. Krintel¹, Johnny Lillelund Raun¹³ and Merete Lund Hetland², ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ³Department of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, ⁴King Christian X Hospital for Rheumatic Diseases, Graasten, Denmark, ⁵Department of Rheumatology, Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ⁷Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ⁸Department of Medicine, Vejle Regional Hospital, Vejle, Denmark, ⁹The DANBIO registry and the Danish Departments of Rheumatology, Odense, Denmark, ¹⁰Department of Rheumatology, Vendsyssel Hospital, Hjørring, Denmark, ¹¹9Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹²Department of Rheumatology, Viborg Regional Hospital, Viborg, Denmark, ¹³King Christian X Hospital for Rheumatic Diseases, South Jutland Hospital, Graasten, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is characterised by progressive destruction of joint bone and loss of periarticularbone mineral. Hand bone loss (HBL) measured by Digital X-ray…
Abstract Number: 2550 • 2016 ACR/ARHP Annual Meeting
Long Persistence of Anti-Drug Antibodies in Adalimumab Treated RA Patients
Joern Kekow¹ and Susanne Drynda², ¹University of Magdeburg, Clinic of Rheumatology, Magdeburg, Germany, ²University of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany
Background/Purpose: The application of biologic substances is subject to a risk to develop antibodies against these structures causing adverse events or loss of efficacy. For…
Abstract Number: 1287 • 2015 ACR/ARHP Annual Meeting
Impact of Participation in Adalimumab Patient Support Program (PSP) on Clinical Outcomes and Predictors of PSP Utilization Among Patients with Rheumatoid Arthritis
Filip van Den Bosch¹, Siegfried Wassenberg², Andrew Östör³, Nupun A. Varothai⁴, Vishvas Garg⁴ and Jasmina Kalabic⁴, ¹Ghent University Hospital, Ghent, Belgium, ²Fachkrankenhaus, Ratingen, Germany, ³Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴AbbVie, North Chicago, IL
Background/Purpose: Adalimumab (ADA) treated rheumatoid arthritis (RA) patients (pts) are offered patient support programs (PSP) to manage their disease. The purpose of this study is…
Abstract Number: 2726 • 2015 ACR/ARHP Annual Meeting
The Effect of Prior Disease Duration and Prior DMARD Use on Treatment Outcomes in Patients with Early or Established Rheumatoid Arthritis
Josef S. Smolen¹, Daniel Aletaha², Su Chen³ and Stefan Florentinus³, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ³AbbVie Inc., North Chicago, IL
Background/Purpose: A delay in effective treatment is known to negatively affect long term treatment outcomes in patients (pts) with rheumatoid arthritis (RA). The purpose of…
Abstract Number: 507 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Adalimumab Therapy in Japanese Patients with Rheumatoid Arthritis
Yosuke Hattori, 4-1-1 Sannomaru, Naka-ku, National Hospital Organization Nagoya Medical, Nagoya, Japan
HIGH RATE OF IMPROVEMENT IN SERUM MATRIX METALLOPROTEINASE-3 LEVELS AT 4 WEEKS PREDICT REMISSION AT 52 WEEKS IN RA PATIENTS WITH ADALIMUMAB THERAPY Background/Purpose : Serum…
Abstract Number: 2769 • 2013 ACR/ARHP Annual Meeting
Clinical Remission After 52 Weeks Of Treatment Is a Predictor Of Adalimumab-Free Disease Control In Patients With Early Rheumatoid Arthritis: Hopeful 2 Study
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Tadamichi Kubo⁶, Aki Kuroki⁷ and Tsutomu Takeuchi⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie, Tokyo, Japan, ⁶Post Marketing Study Group, Medical, AbbVie GK, Tokyo, Japan, ⁷Medical Affairs, AbbVie GK, Tokyo, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Although it is possible to achieve remission or low disease activity (LDA) with the combination of methotrexate (MTX) and biologics for many patients with…
Abstract Number: 2326 • 2013 ACR/ARHP Annual Meeting
Head-To-Head Comparison Of Subcutaneous Abatacept Versus Adalimumab On Background Methotrexate In RA: Blinded Two Year Results From The Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjectswith Background Methotrexate) study
Michael E. Weinblatt¹, Michael H Schiff², Robert Valente³, Désirée M. van der Heijde⁴, Gustavo Citera⁵, Ayanbola Elegbe⁶, Michael A Maldonado⁶ and Roy Fleischmann⁷, ¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Denver, CO, ³Arthritis Center of Nebraska, Lincoln, NE, ⁴Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Princeton, NJ, ⁷University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) is the first 2 year, active comparator study in RA patients utilizing…
Abstract Number: 476 • 2013 ACR/ARHP Annual Meeting
Two-Year Results From The Ample Trial: Low Disease Activity and Association Between Remission and Changes In Physical Function and Radiographic Outcomes With Subcutaneous Abatacept Or Adalimumab
Roy Fleischmann¹, M Schiff², M E Weinblatt³, M Maldonado⁴, E Massarotti⁵ and Y Yazici⁶, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²University of Colorado, Denver, CO, ³Brigham & Women's Hospital, Boston, MA, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵Brigham and Women's Hospital, Boston, MA, ⁶New York University Hospital for Joint Diseases, New York, NY
Background/Purpose: Remission and low disease activity (LDA) are now more achievable goals in RA. Year 1 data from the head-to-head AMPLE (Abatacept vs Adalimumab Comparison…
Abstract Number: 424 • 2013 ACR/ARHP Annual Meeting
2-Year Results From The Ample (Abatacept versus Adalimumab Comparison in Biologic-Naïve RA Patients with Background Methotrexate) Trial: Changes In Patient-Reported Outcomes In Response To Subcutaneous Abatacept Or Adalimumab In Rheumatoid Arthritis
Roy Fleischmann¹, ME Weinblatt², M Schiff³, D Khanna⁴, MA Maldonado⁵, A Nadkarni⁶ and Daniel Furst⁷, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³University of Colorado, Denver, CO, ⁴University of Michigan, Ann Arbor, MI, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Bristol-Myers Squibb, Plainsboro, NJ, ⁷University of California at Los Angeles, Los Angeles, CA
Background/Purpose: RA is a debilitating disease that can impact health-related quality of life (HRQoL) through impairment of activity, loss of independence and reduced work productivity.…
Abstract Number: 2449 • 2012 ACR/ARHP Annual Meeting
Head to Head Comparison of Subcutaneous Abatacept Versus Adalimumab in the Treatment of Rheumatoid Arthritis: Key Efficacy and Safety Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Michael E. Weinblatt¹, Michael H. Schiff², Roy Fleischmann³, Robert Valente⁴, Désirée van der Heijde⁵, Gustavo Citera⁶, Cathy Zhao⁷ and Michael A. Maldonado⁸, ¹Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ²Rheumatology Division, University of Colorado, Denver, CO, ³Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁴Arthritis Center of Nebraska, Lincoln, NE, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Medical Strategy, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose : The availability of multiple biologic agents to treat rheumatoid arthritis (RA) has created a need for comparative assessment. AMPLE (Abatacept Versus Adalimumab Comparison…
Abstract Number: 1832 • 2012 ACR/ARHP Annual Meeting
Evaluating the Cost-Effectiveness of Personalized Treatment with Adalimumab Using Serum Drug Levels in Rheumatoid Arthritis Patients
Charlotte L. M. Krieckaert¹, Sandhya C. Nair², M. T. Nurmohamed³, Carlo J.J. van Dongen¹, Willem F. Lems⁴, Floris P.J.G. Lafeber², J.W.J. Bijlsma⁵, Gertjan Wolbink¹ and Paco M.J. Welsing⁶, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatology & Clinical Immunology, F02.127, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The high costs of biologicals warrant a rational use of these drugs, preferably by tailoring them to the individual patient. The objective was to…
Abstract Number: 1342 • 2012 ACR/ARHP Annual Meeting
Changes in Patient Reported Outcomes in Response to Subcutaneous Abatacept or Adalimumab in Rheumatoid Arthritis: Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael E. Weinblatt², Michael H. Schiff³, Dinesh Khanna⁴, Daniel Furst⁵ and Michael A. Maldonado⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Rheumatology Division, University of Colorado, Denver, CO, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁶Medical Strategy, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Rheumatoid arthritis (RA) is associated with pain, fatigue, disability and functional loss, which can significantly impact a patient's health-related quality of life (HRQoL). Patient-Reported…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].